AstraZeneca Divests Gastrointestinal Drug For $215M
AstraZeneca LP said on Thursday that it had reached a $215 million deal to divest the global rights, outside the United States, for its gastroenterology medicine Entocort to Swiss pharmaceutical company...To view the full article, register now.
Already a subscriber? Click here to view full article